TALTZ (Eli Lilly Australia Pty Ltd)
Product name
TALTZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
97 (255 working days)
Active ingredients
ixekizumab
Registration type
EOI
Indication
TALTZ (solution for injection) is now also indicated for:
Non-radiographic axial spondyloarthritis
TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI evidence, who have responded inadequately to, or are intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).